ArcticZymes Technologies — Investor Presentation 2023

Nov 23, 2023

SEB Healthcare Seminar

CEO Michael Akoh

Agenda

At a glance

Markets

Our customers

Products and pipeline

Spotlight: SAN

Financial performance

ArcticZymes Technologies

Shaped by the Arctic – global outreach

• HQ in Tromsø, Norway
• World class commercial supplier of novel and high-quality enzymes
• ISO 13485 certified and manufacturing according to GMP guidelines
• 20+ years' experience
• 65+ employees
• Direct sales in most markets
• Publicly listed, OSE:AZT

On a Mission

Focused and partner driven strategy

A global leading specialist enzymes partner within Advanced Therapies and Molecular Diagnostics

Be a catalyst for innovation and value creation for our partners

A Growing Market

Targeting high-growth Biomanufacturing and Molecular diagnostics segments

Biomanufacturing Focus on Cell & Gene Therapies

Market Size 2023 – 2030 5 Bil USD – 30 Bil USD Nucleases 500 million US dollars (CAGR 20%)

Bio-manufacturing

• Enzymes utilized in the production process of gene therapy
• FDA expects more 200 INDs/year and 10- 20 approvals/year from 2025 within CGT

Molecular diagnostics

Enzymes for driving assay technologies and innovation

• New technologies and chemistry driving growth

Molecular Tools Molecular Research & Diagnostics

Market Size 2023 – 2027 23 – 30 Bil USD (CAGR. 5.4%)

B2B Value chain

Biomanufacturing and Molecular Tools customers

Our Solutions

Unique enzymes for applications in the workflow

Building out the product portfolio

*

Looking further ahead – beyond 2023

❑ Expand Biomanufacturing capabilities

• o SAN product lifecycle management
• o Value through Quality Transitions & DMF
• o RNA therapeutics generic & novel
• o Nucleases and Proteinases

❑ Expand Molecular Tools capabilities

• o Complete MDx workflow assembly
• o Expand to NGS variants
• o Push new RT and Taq ++
• o Hot Start / Formulations

SAN Salt Active Nuclease

Product Placement - Biomanufacturing

Case Study – viral vector manufacturing (CGT)

INTRODUCING SAN HQ GMP Salt Active Nuclease with superior performance

• The Salt & Nuclease Paradox:
• As salt concentration increases, conditions for DNA clearance improve, but enzyme function decreases
• This "paradox" is resolved by SAN HQ GMP
• Ability to clear DNA from viral vectors increases as salt concentration rises

Growing the Biomanufacting segment From ISO13485 to GMP grade

Growing the SAN business

GMP grade production expands addressable market

Drug Master File for SAN HQ GMP

Showing our commitment to our Biomanucturing customers

• A drug master file (DMF) is a submission to the FDA that contains confidential, detailed information about:
• Facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of one or more human drugs.
• Provide information to the FDA about these aspects of a drug product without revealing trade secrets to the customer.

In short, the benefits of having a DMF are:

• Improves credibility and reputation
• Help customers streamline drug development and approval process
• Accelerate sales cycle
• Levels playing field against major competitors

Financial Performance

Financial Performance

Organisation

Recruitment drive completed

Well postioned to deliver long term growth

Attractive market space

• Operating in growth segments
• New therapies within CGT and mRNA

Strong Foundation

• Strong cash position and high margins
• Experienced team
• Reputation, brand and security of supply
• Global sales channels customer base
• Regulatory compliance

Growth leverage

• Innovation driven by biotechnology toolbox
• Organic growth but with an eye out for M&A
• Market and partner driven
• Compliance upgrade to GMP grade